| Ident. | Authors (with country if any) | Title |
|---|
| 000001 (2021) |
Daniel G. Dauner ; Kim Nichols Dauner | Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. |
| 000004 (2021) |
Stéphane Honoré [France] ; Philippe Gautret [France] | Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients. |
| 000005 (2021) |
Elisa Baranski Lamback [Brésil] ; Monica Amorim De Oliveira [Brésil] ; Andrea Ferreira Haddad [Brésil] ; André Filipe Marcondes Vieira [Brésil] ; Armando Leão Ferreira Neto [Brésil] ; Taciana Da Silva Maia [Brésil] ; Juliana De Rezende Chrisman [Brésil] ; Pedro Pimenta De Mello Spineti [Brésil] ; Marco Antonio De Mattos [Brésil] ; Eduardo Costa [Brésil] | Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. |
| 000011 (2021) |
Matthieu Million [France] ; Audrey Giraud-Gatineau [France] ; Jean-Christophe Lagier [France] ; Philippe Parola [France] ; Philippe Gautret [France] ; Didier Raoult [France] | Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. |
| 000014 (2021) |
Julio Echarte-Morales [Espagne] ; Carlos Minguito-Carazo [Espagne] ; Samuel Del Castillo-García [Espagne] ; Javier Borrego-Rodríguez [Espagne] ; Miguel Rodríguez-Santamarta [Espagne] ; Enrique Sánchez-Mu Oz [Espagne] ; Rubén Bergel-García [Espagne] ; Clea González-Maniega [Espagne] ; Silvia Prieto-González [Espagne] ; Paula Menéndez-Suarez [Espagne] ; Elena Tundidor-Sanz [Espagne] ; Tomás Benito-González [Espagne] ; Felipe Fernández-Vázquez [Espagne] | Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. |
| 000018 (2021) |
Amaya García-Fernández [Espagne] ; Pablo Ramos-Ruiz [Espagne] ; Alicia Ibá Ez-Criado [Espagne] ; Scar Moreno-Pérez [Espagne] ; Cristina Cambra-Poveda [Espagne] ; Juan Gabriel Martínez-Martínez [Espagne] | [Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients]. |
| 000042 (2021) |
Amaya García-Fernández [Espagne] ; Pablo Ramos-Ruiz [Espagne] ; Alicia Ibá Ez-Criado [Espagne] ; Scar Moreno-Pérez [Espagne] ; Cristina Cambra-Poveda [Espagne] ; Juan Gabriel Martínez-Martínez [Espagne] | Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients. |
| 000044 (2021) |
Jason D. Goldman [États-Unis] ; George Diaz [États-Unis] ; Walter J. Urba [États-Unis] | Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. |
| 000055 (2021) |
Tuan V. Nguyen [Australie] | Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load. |
| 000057 (2021) |
Nobuaki Mori [Japon] ; Mitsuya Katayama [Japon] ; Shigenari Nukaga [Japon] | Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. |
| 000073 (2021) |
Alexis Lacout [France] ; Valere Lounnas [Allemagne] ; Christian Perronne [France] | Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients. |
| 000085 (2021) |
Nijad Bakhshaliyev [Turquie] ; Ramazan Özdemir [Turquie] | The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course. |
| 000097 (2021) |
Jack Cook [États-Unis] ; Milton L. Pressler [États-Unis] ; Bharat Damle [États-Unis] ; Demissie Alemayehu [États-Unis] ; Charles A. Knirsch [États-Unis] | The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. |
| 000138 (2021) |
Katharina Habler [Allemagne] ; Mathias Brügel [Allemagne] ; Daniel Teupser [Allemagne] ; Uwe Liebchen [Allemagne] ; Christina Scharf [Allemagne] ; Ulf Schönermarck [Allemagne] ; Michael Vogeser [Allemagne] ; Michael Paal [Allemagne] | Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. |
| 000149 (2021) |
Amir Sarayani [États-Unis] ; Brian Cicali [États-Unis] ; Carl H. Henriksen [États-Unis] ; Joshua D. Brown [États-Unis] | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. |
| 000150 (2021) |
Philippe Gautret [France] ; Stéphane Honoré [France] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. |
| 000193 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Hervé Chaudet [France] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. |
| 000194 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Stéphane Honoré [France] ; Yanis Roussel [France] ; Matthieu Million [France] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000224 (2021) |
Matthieu Million [France] ; Yanis Roussel [France] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al. |
| 000225 (2021) |
Alexis Lacout [France] ; Pierre Yves Marcy [France] ; Christian Perronne [France] | Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al. |
| 000227 (2021) |
Iwein Gyselinck [Belgique] ; Wim Janssens [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] | Rationale for azithromycin in COVID-19: an overview of existing evidence. |
| 000234 (2021) |
Carlos Diaz-Arocutipa [Pérou] ; Ana Bra Ez-Condorena [Pérou] ; Adrian V. Hernandez [Pérou, États-Unis] | QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. |
| 000242 (2021) |
Basma S. Mansour [Égypte] ; Noha A. Salem [Égypte] ; Ghada Abdel Kader [Égypte] ; Gamal Abdel-Alrahman [Égypte] ; Omayma M. Mahmoud [Égypte] | Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model. |
| 000249 (2021) |
Bianza Moise Bakadia ; Feng He [République populaire de Chine] ; Tiatou Souho [Togo] ; Lallepak Lamboni [Togo] ; Muhammad Wajid Ullah [République populaire de Chine] ; Biaou Ode Boni [République populaire de Chine] ; Abeer Ahmed Qaed Ahmed [République populaire de Chine] ; Biampata Mutu Mukole ; Guang Yang [République populaire de Chine] | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. |
| 000266 (2021) |
Jean-Michel Scherrmann [France] | Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 Therapy. |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000334 (2021) |
Jérôme Montnach [France] ; Isabelle Bar [France] ; Flavien Charpentier [France] ; Michel De Waard [France] ; Gildas Loussouarn [France] | Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. |
| 000337 (2021) |
Kazimieras Maneikis [Lituanie] ; Ugne Ringeleviciute [Lituanie] ; Justinas Bacevicius [Lituanie] ; Egle Dieninyte-Misiune [Lituanie] ; Emilija Burokaite [Lituanie] ; Gintare Kazbaraite [Lituanie] ; Marta Monika Janusaite [Lituanie] ; Austeja Dapkeviciute [Lituanie] ; Andrius Zucenka [Lituanie] ; Valdas Peceliunas [Lituanie] ; Lina Kryzauskaite [Lituanie] ; Vytautas Kasiulevicius [Lituanie] ; Donata Ringaitiene [Lituanie] ; Birute Zablockiene [Lituanie] ; Tadas Zvirblis [Lituanie] ; Germanas Marinskis [Lituanie] ; Ligita Jancoriene [Lituanie] ; Laimonas Griskevicius [Lituanie] | Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan. |
| 000356 (2021) |
Mohamed O. Saad [Qatar] | Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000364 (2021) |
Pravash Budhathoki [Népal] ; Dhan Bahadur Shrestha [Népal] ; Sitaram Khadka [Népal] ; Era Rawal [Népal] | Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis. |
| 000399 (2021) |
Brahim Halil Özdemir [Turquie] ; Bülent Özlek [Turquie] ; Mehmet Burak Özen [Turquie] ; Ramazan Gündüz [Turquie] ; Nurullah Çetin [Turquie] ; Ali R Za Bilge [Turquie] | Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. |
| 000401 (2021) |
Thomas F. O'Connell [États-Unis] ; Christopher J. Bradley [États-Unis] ; Amr E. Abbas [États-Unis] ; Brian D. Williamson [États-Unis] ; Akash Rusia [États-Unis] ; Adam M. Tawney [États-Unis] ; Rick Gaines [États-Unis] ; Jason Schott [États-Unis] ; Alex Dmitrienko [États-Unis] ; David E. Haines [États-Unis] | Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. |
| 000408 (2021) |
Christine Johnston [États-Unis] ; Elizabeth R. Brown [États-Unis] ; Jenell Stewart [États-Unis] ; Helen C Stankiewicz Karita [États-Unis] ; Patricia J. Kissinger [États-Unis] ; John Dwyer [États-Unis] ; Sybil Hosek [États-Unis] ; Temitope Oyedele [États-Unis] ; Michael K. Paasche-Orlow [États-Unis] ; Kristopher Paolino [États-Unis] ; Kate B. Heller [États-Unis] ; Hannah Leingang [États-Unis] ; Harald S. Haugen [États-Unis] ; Tracy Q. Dong [États-Unis] ; Anna Bershteyn [États-Unis] ; Arun R. Sridhar [États-Unis] ; Jeanne Poole [États-Unis] ; Peter A. Noseworthy [États-Unis] ; Michael J. Ackerman [États-Unis] ; Susan Morrison [États-Unis] ; Alexander L. Greninger [États-Unis] ; Meei-Li Huang [États-Unis] ; Keith R. Jerome [États-Unis] ; Mark H. Wener [États-Unis] ; Anna Wald [États-Unis] ; Joshua T. Schiffer [États-Unis] ; Connie Celum [États-Unis] ; Helen Y. Chu [États-Unis] ; Ruanne V. Barnabas [États-Unis] ; Jared M. Baeten [États-Unis] | Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. |
| 000409 (2021) |
Michael J. Keane [Australie] | Hydroxychloroquine with or without Azithromycin in Covid-19. |
| 000410 (2021) |
Rahul Choudhary [Oman] ; Gopal K. Bohra [Oman] ; Deepak Kumar [Oman] | Hydroxychloroquine with or without Azithromycin in Covid-19. |
| 000411 (2021) |
Alexandre B. Cavalcanti [Brésil] ; Otávio Berwanger [Brésil] ; Fernando G. Zampieri [Brésil] | Hydroxychloroquine with or without Azithromycin in Covid-19. Reply. |
| 000421 (2021) |
Elif Tanriverd [Turquie] ; Mustafa Çörtük [Turquie] ; Binnaz Zeynep Yildirim [Turquie] ; Efsun Gonca U Ur Chousein [Turquie] ; Demet Turan [Turquie] ; Halit Çinarka [Turquie] ; Mehmet Akif Özgül [Turquie] ; Erdo An Çetinkaya [Turquie] | Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data |
| 000448 (2021) |
Philippe Gautret [France] ; Jean-Christophe Lagier [France] ; Stéphane Honoré [France] ; Van Thuan Hoang [Viêt Nam] ; Philippe Colson [France] ; Didier Raoult [France] | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. |
| 000479 (2021) |
Carlos Gustavo Wambier [États-Unis] | Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000527 (2021) |
Luigi Moschini [Italie] ; Marco Loffi [Italie] ; Valentina Regazzoni [Italie] ; Giuseppe Di Tano [Italie] ; Elisa Gherbesi [Italie] ; Gian Battista Danzi [Italie] | Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. |
| 000532 (2021) |
Shadma Wahab ; Md Faruque Ahmad ; Arshad Hussain ; Shazia Usmani ; Ambreen Shoaib ; Wasim Ahmad | Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management. |
| 000536 (2021) |
Thibault Fiolet [France] ; Anthony Guihur [Suisse] ; Mathieu Edouard Rebeaud [Suisse] ; Matthieu Mulot [Suisse] ; Nathan Peiffer-Smadja [France] ; Yahya Mahamat-Saleh [France] | Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. |
| 000537 (2021) |
Thibault Fiolet [France] ; Anthony Guihur [Suisse] ; Mathieu Edouard Rebeaud [Suisse] ; Matthieu Mulot [Suisse] ; Nathan Peiffer-Smadja [France] ; Yahya Mahamat-Saleh [France] | Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. |
| 000540 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Philippe Colson [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann. |
| 000541 (2021) |
Matthieu Million [France] ; Yanis Roussel [France] ; Philippe Gautret [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. |
| 000542 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. |
| 000543 (2021) |
Seyed Parsa Eftekhar [Iran] ; Sohrab Kazemi [Iran] ; Mohammad Barary [Iran] ; Mostafa Javanian [Iran] ; Soheil Ebrahimpour [Iran] ; Naghmeh Ziaei [Iran] | Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients. |
| 000558 (2021) |
Alexandre Elias Malek [États-Unis] ; Bruno P. Granwehr [États-Unis] | Doxycycline as an Alternative to Azithromycin in Elderly Patients. |
| 000565 (2021) |
Iwein Gyselinck [Belgique] ; Laurens Liesenborghs [Belgique] ; Ewout Landeloos [Belgique] ; Ann Belmans [Belgique] ; Geert Verbeke [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] ; W. Janssens [Belgique] | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. |
| 000568 (2021) |
Vong Sok [États-Unis] ; Florence Marzan [États-Unis] ; David Gingrich [États-Unis] ; Francesca Aweeka [États-Unis] ; Liusheng Huang [États-Unis] | Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. |
